LLNL has a long history of leveraging unique capabilities and expertise for a variety of mission-critical challenges. Several specialized resources are being leveraged to support the fight against COVID-19.
Mobile (truck-mounted) biolaboratory
- We maintain a truck-mounted biolaboratory for emergency deployments. This mobile laboratory is outfitted with a one-pass HEPA-filtered glovebox, three Class II biosafety cabinets, two autoclaves, freezers, robotics for liquid handling, PCR machines and standard biolab equipment.
Biosafety Level 3 laboratory
- Onsite at LLNL is a Biosafety Level 3 laboratory that enables efficient testing of promising therapeutic candidates for pathogens such as COVID-19.
Genomic sequencing and bioinformatics
- We have state-of-the-art DNA sequencing capabilities to perform viral sequencing to identify outbreak strains, mutations and genes from COVID-19 infected patients. Our bioinformatics tools use the new sequence information to conduct rapid transmission tracing, analyze phylogenetic relationships and design sensitive signatures for DNA-based diagnostic assays.
3D printing and rapid prototyping
- Our engineering research efforts and capabilities can support a broad range of response activities, including:
- Additive manufacturing, material development, systems design and design optimization
- Nanoscale implantable devices, biocompatible materials and electro-bio interfaces
- Design, fabrication, characterization, packaging and integration of biological micro- and nano-systems
- Design and development of tiny electromechanical devices, electronics, photonics, structures and actuators
- LLNL is a founding member of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a partnership with the Frederick National Laboratory for Cancer Research, the University of California, San Francisco and GlaxoSmithKline. The consortium has successfully demonstrated new computational approaches for rapidly designing new drug molecules for cancer therapies in weeks (rather than years). These new design tools are being applied to optimization of the safety and effectiveness of potential drug molecules discovered in large-scale COVID-19 computational screens.
- The American Heart Association (AHA) and LLNL have formed a strategic business partnership to overcome the burden of drug discovery, cost and access. The two organizations will leverage the world’s most powerful supercomputers to accelerate drug discovery. LLNL scientists and engineers in collaboration with AHA-funded scientists will create a simulated environment that rapidly and precisely predicts how drugs bind to their target proteins and will test these predictions in experimental systems to generate a robust drug pipeline of new and targeted therapies.
- Accelerated publication - Quantitative form and fit of N95 filtering facepiece respirators are retained and coronavirus surrogate is inactivated after heat treatments
- Accelerated publication - Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing
- January 19, 2021 - LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
- November 18, 2020 - Model for COVID-19 drug discovery a Gordon Bell finalist
- November 12, 2020 - LLNL welcomes 'Ruby' supercomputer for national nuclear security mission and COVID-19 research
- November 4, 2020 - Mammoth computing cluster to aid COVID research
- October 19, 2020 - AI gets a boost via LLNL, SambaNova collaboration
- October 7, 2020 - Corona supercomputer gets funding for COVID-19 work
- June 25, 2020 - Lab technologies help fight COVID-19
- June 9, 2020 - Lab, BMI produce FDA-approved emergency ventilator
- June 8, 2020 - Multi-lab research to improve COVID-19 diagnostics
- May 29, 2020 - Lab team studies calibrated AI and deep learning models to more reliably diagnose and treat disease
- May 21, 2020 - Lab provides assistance in national swab shortage
- May 19, 2020 - COVID-19 research goes public through new portal
- May 14, 2020 - Deactivating coronavirus on N95 respirators for reuse
- May 1, 2020 - LLNL’s new machine learning platform generates novel COVID-19 antibody sequences for experimental testing
- April 29, 2020 - LLNL develops ‘stopgap’ ventilator for COVID-19 use
- April 21, 2020 - Upgrades for LLNL supercomputer from AMD, Penguin Computing aid COVID-19 research
- March 26, 2020 - New partnership to unleash U.S. supercomputing resources in the fight against COVID-19
- March 26, 2020 - Lab antibody, anti-viral research aids COVID-19 response
- February 3, 2020 - Lawrence Livermore researchers release 3D protein structure predictions for the novel coronavirus
- January 13, 2021 - Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis
- November 4, 2020 - AMD-Supermicro-Cornelis (Omni-Path) ‘Mammoth’ cluster at LLNL targets COVID-19
- May 5, 2020 - Advanced manufacturing innovation helps industry in COVID-19 fight
- May 5, 2020 - 3-D printed COVID-19 test swabs pass their own tests
- May 4, 2020 - Swab Shortage: FATHOM & Abiogenix Bridge the Gap with 3D Printed NP Swabs
- April 14, 2020 - LLNL’s Jim Brase explains how DOE labs are fighting (and coping with) COVID-19
- February 5, 2020 - Coronavirus: Lawrence Livermore Lab researchers examine virus in hopes of blocking, treating it
For more information about the U.S. government's response to COVID-19, see coronavirus.gov and usa.gov/coronavirus. For the latest public health and safety information from the Centers for Disease Control and Prevention, see cdc.gov/coronavirus.